The process of developing a new drug is a long journey that requires the collaboration of numerous experts, starting from basic research to drug manufacturing, clinical trials, and approval. In addition, it is an industry with an extremely low probability of success despite the investment of enormous resources. However, it is also an area that must be accomplished in order to live like human beings.

The answer to my concerns for developing innovative new drugs starting in 2007 was “Open Innovation.” Since it is difficult to achieve success of the entire process of new drug development with only internal resources as a startup with limited physical resources. Accordingly, AbFinder Therapeutics Co., Ltd. was established.

In order to achieve the ultimate goal of “improving human health through the development of innovative new drugs,” we aim to take charge of the axis where we can demonstrate the most expertise in the new drug development process. Based on the innovative platform technologies that can solve the unmet needs of biopharmacuetical industry, we will successfully develop innovative new drugs through collaboration with global pharmaceutical companies. Through this process, we will become the global No. 1 biopharmaceutical platform company.

AbFinder Therapeutics Co., Ltd. President & CEO   Ph.D Seong-Gu Han